Article

Nicox to refocus DMD treatment

Nicox S.A. has decided to re-focus its naproxcinod development efforts, granting an undisclosed financial partner the right to enter into a period of exclusive evaluation to assess the potential development of the drug and of next-generation nitric oxide (NO)-donors outside the ophthalmology area.

 

Sophia Antipolis, France-Nicox S.A. has decided to re-focus its naproxcinod development efforts, granting an undisclosed financial partner the right to enter into a period of exclusive evaluation to assess the potential development of the drug and of next-generation nitric oxide (NO)-donors outside the ophthalmology area.

The evaluation will be entirely funded by the undisclosed partner and will be focused initially on Duchenne muscular dystrophy (DMD). Nicox has granted the undisclosed partner the exclusive right-should the results of the evaluation be satisfactory to the partner-to invest at the end of the evaluation period in the drug and next-generation NO-donors outside ophthalmology through an independent structure.

Nicox will not pursue any other development activities or discussions with third parties related to the drug, which is a Cyclooxygenase-Inhibiting Nitric Oxide-Donating anti-inflammatory candidate.

In October, the European Commission granted Orphan Drug Designation for the drug for the treatment of DMD.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.